X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (57) 57
life sciences & biomedicine (38) 38
humans (20) 20
female (19) 19
male (18) 18
middle aged (17) 17
pulmonary/respiratory (15) 15
diabetes (14) 14
aged (13) 13
diabetes mellitus (12) 12
endocrinology & metabolism (12) 12
analysis (11) 11
double-blind method (11) 11
treatment outcome (11) 11
type 2 diabetes (11) 11
respiratory system (10) 10
physical sciences (9) 9
pulmonary disease, chronic obstructive - drug therapy (9) 9
clinical trials (8) 8
diabetes mellitus, type 2 - drug therapy (8) 8
multidisciplinary sciences (8) 8
science & technology - other topics (8) 8
adult (7) 7
genetic diversity (7) 7
glycopyrrolate - analogs & derivatives (7) 7
medicine (7) 7
patients (7) 7
primers (7) 7
studies (7) 7
technology (7) 7
chemistry (6) 6
drug therapy (6) 6
genetic markers (6) 6
glycopyrrolate - administration & dosage (6) 6
glycopyrrolate - adverse effects (6) 6
heart failure (6) 6
heterozygosity (6) 6
life sciences (6) 6
plant sciences (6) 6
polymer science (6) 6
species (6) 6
adamantane - analogs & derivatives (5) 5
bronchodilator agents - administration & dosage (5) 5
cardiac & cardiovascular systems (5) 5
cardiovascular disease (5) 5
cardiovascular system & cardiology (5) 5
clinical medicine (5) 5
comparative analysis (5) 5
dapagliflozin (5) 5
drug administration schedule (5) 5
drug therapy, combination (5) 5
evolution (5) 5
general & internal medicine (5) 5
genomes (5) 5
glucose (5) 5
glucose monitoring (5) 5
glycopyrrolate - therapeutic use (5) 5
hypoglycemia (5) 5
hypoglycemic agents - therapeutic use (5) 5
indans - administration & dosage (5) 5
indans - adverse effects (5) 5
materials science (5) 5
medical research (5) 5
metformin (5) 5
mortality (5) 5
phylogeny (5) 5
population genetics (5) 5
quinolones - administration & dosage (5) 5
quinolones - adverse effects (5) 5
research article (5) 5
science (5) 5
adamantane - adverse effects (4) 4
administration, inhalation (4) 4
benzhydryl compounds - adverse effects (4) 4
biodiversity (4) 4
blood glucose - drug effects (4) 4
blood glucose - metabolism (4) 4
bronchodilator agents - adverse effects (4) 4
bronchodilator agents - therapeutic use (4) 4
conservation genetics (4) 4
diabetes mellitus, type 2 - blood (4) 4
diabetes mellitus, type 2 - epidemiology (4) 4
dipeptides - adverse effects (4) 4
dosage and administration (4) 4
genes (4) 4
glucosides - adverse effects (4) 4
glycopyrronium (4) 4
heart diseases (4) 4
hemoglobin (4) 4
hypoglycemia - chemically induced (4) 4
hypoglycemic agents - adverse effects (4) 4
indans - therapeutic use (4) 4
laboratories (4) 4
materials science, textiles (4) 4
metformin - adverse effects (4) 4
microsatellites (4) 4
muscarinic antagonists - adverse effects (4) 4
polymer sciences (4) 4
pulmonary disease, chronic obstructive - physiopathology (4) 4
quinolones - therapeutic use (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet respiratory medicine, ISSN 2213-2600, 05/2013, Volume 1, Issue 3, pp. 199 - 209
Journal Article
The lancet respiratory medicine, ISSN 2213-2600, 03/2013, Volume 1, Issue 1, pp. 51 - 60
Journal Article
Respiratory medicine, ISSN 0954-6111, 10/2013, Volume 107, Issue 10, pp. 1558 - 1567
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 22, pp. 2497 - 2506
Journal Article
Chest, ISSN 0012-3692, 2014, Volume 145, Issue 3, pp. 403A-1 - 403A-2
Journal Article
International journal of chronic obstructive pulmonary disease, ISSN 1178-2005, 02/2014, Volume 9, pp. 215 - 228
Background: Addition of a second bronchodilator from a different pharmacological class may benefit patients with moderate-to-severe chronic obstructive... 
Bronchodilation | Indacaterol | Inhalation therapy | Breezhaler | Glycopyrronium | COPD | Life Sciences & Biomedicine | Respiratory System | Science & Technology | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Area Under Curve | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Female | Indans - administration & dosage | Inspiratory Capacity | Bronchodilator Agents - adverse effects | Drug Therapy, Combination | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Drug Administration Schedule | Europe | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Muscarinic Antagonists - administration & dosage | Vital Capacity | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Dosage and administration | Glycopyrrolate | Drug therapy, Combination | Drug therapy | Comparative analysis | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2018, Volume 71, Issue 23, pp. 2628 - 2639
BACKGROUND Randomized trials demonstrated a lower risk of cardiovascular (CV) events with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with... 
heart failure | SEVERE HYPOGLYCEMIA | SULFONYLUREA | death | INITIATION | SGLT-2 inhibitor | diabetes mellitus | sodium glucose cotransporter-2 inhibitors | ALL-CAUSE MORTALITY | ORGANIZATION | JAPANESE HOSPITAL DATABASE | ASIA | LOWER RISK | DPP-4 INHIBITORS | observational studies | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Sodium-Glucose Transporter 2 Inhibitors - pharmacology | Male | Diabetes Mellitus, Type 2 - epidemiology | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Internationality | Cardiovascular Diseases - blood | Cardiovascular Diseases - epidemiology | Adult | Female | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Electronic Health Records | Cohort Studies | Glucose | Chemical vapor deposition | Analysis | Dextrose | Heart | Drugs | Laboratories | Identification methods | Personal health | Clinical trials | Medical records | Subgroups | Matching | Confidence intervals | Databases | Risk assessment | Diuretics | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Heart failure | Health insurance | Stroke | Payment systems | Diabetes mellitus | Mortality | Health risks | Patients | Prescription drugs | Hospitals | Inhibitors | Sodium | Death | Diabetes | Clinical medicine | Cardiovascular diseases | Pharmaceuticals
Journal Article
Chest, ISSN 0012-3692, 2014, Volume 145, Issue 3, pp. 402A-1 - 402A-2
Journal Article
Current medical research and opinion, ISSN 1473-4877, 11/2013, Volume 30, Issue 3, pp. 493 - 508
Journal Article
Diabetes care, ISSN 1935-5548, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
Journal Article